Real-world data show no significant differences in overall survival between patients with or without cytogenetic risk factors ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

This next-generation ROS1 tyrosine kinase inhibitor previously received breakthrough therapy and orphan drug designations for ...